Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
WNW
News for the people
Downtown
Magazine PRO
23.7
C
London
Thursday, June 12, 2025
Home
Refund Policy
Privacy Policy
Terms & Conditions
Submit Your Press Releases (Free)
Sponsored Posts
About
Facebook
Instagram
Twitter
Youtube
WNW
News for the people
Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
Subscribe
WNW
News for the people
Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
Subscribe
Home
Tags
Eisai’s
Tag: Eisai’s
Japan – Eisai’s “URECE(R)” (Dotinurad) Approved in China for Gout Patients...
Leslie Atkins
-
December 12, 2024
0
Japan – Eisai’s Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected...
Editor
-
November 5, 2024
0
Japan – Eisai’s Antiepileptic Drug Fycompa Approved in China for Adjunctive...
May 14, 2024
0
Japan – Eisai’s Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
April 18, 2024
0
Japan – Eisai’s Sales Subsidiary Collaborates with Ministry of Public Health...
December 1, 2023
0
Japan – Eisai’s Initiatives for Developing New Medicines for Neglected Tropical...
May 27, 2023
0
Japan – FDA Accepts Eisai’s Filing of a Supplemental Biologics License...
Editor
-
March 6, 2023
0
Japan – Eisai’s Sales Subsidiary Collaborates with Thai Life Insurance to...
Editor
-
November 5, 2022
0
Japan – Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met...
September 28, 2022
0
Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy...
January 19, 2022
0
Eisai’s Statement of Commitment for Carbon Neutrality by 2040
May 11, 2021
0
Get $10 by answering a Simple Survey.
Click Here